Company Nicox SA

ALCOX

FR0013018124

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Nicox SA

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Real-time Euronext Paris Other stock markets 01:14:07 26/06/2024 pm IST			5-day change	1st Jan Change
0.218 ^EUR	+0.69%		-11.02%	-50.68%

19/06	Nicox: successful capital increase	CF
30/05	Nicox : launch of a capital increase	CF

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Number of employees: 28

EUR in Million	2021	Weight	2022	Weight	Delta
Pharmaceutical Research and Development 100.0 %	9	100.0 %	5	100.0 %	-38.93%

Managers	Title	Age	Since
Gavin M. Spencer CEO	Chief Executive Officer	53	01/05/01
Michele Garufi FOU	Founder	70	15/96/15
Sandrine Gestin DFI	Director of Finance/CFO	56	01/99/01
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	13/21/13

Members of the board	Title	Age	Since
Les Kaplan BRD	Director/Board Member	73	01/14/01
Michele Garufi FOU	Founder	70	15/96/15
Jean-François Labbé CHM	Chairman	73	16/10/16
Gavin M. Spencer CEO	Chief Executive Officer	53	01/05/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	50,170,498	46,850,128 ( 93.38 %)	288,965 ( 0.5760 %)	93.38 %

Name	Equities	%	Valuation
Armistice Capital LLC 5.413 %	2,722,947	5.413 %	997 661 €
HBM Partners AG 3.962 %	1,992,649	3.962 %	730 087 €
Michele Garufi 1.207 %	607,051	1.207 %	222 417 €
NICOX SA 0.6184 %	311,067	0.6184 %	113 972 €
Erasmus Gestion SAS 0.3777 %	190,000	0.3777 %	69 614 €
Les Kaplan 0.1631 %	82,034	0.1631 %	30 056 €
Gestys SA 0.1193 %	60,000	0.1193 %	21 983 €
Andbank Wealth Management SGIIC SAU 0.0861 %	43,300	0.0861 %	15 865 €

Name	Equities	%	Valuation
NICOX SA 0.62%	311,067	0.62%	113,972 $

Nicox SA

Emerald Square Sundesk Sophia Antipolis

06410, Biot

+33 4 97 24 53 00

http://www.nicox.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2165 EUR

Average target price

1 EUR

Spread / Average Target

+361.89%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
NICOX SA	-50.68%	1.46Cr
KYOWA KIRIN CO. LTD.	+17.03%	910.9Cr
SK BIOPHARMACEUTICALS CO., LTD.	-24.00%	443.59Cr
YUHAN CORPORATION	+13.37%	423.81Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+31.17%	403.4Cr
INDIVIOR PLC	+7.51%	214.27Cr
BETTA PHARMACEUTICALS CO., LTD.	-34.04%	190.17Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.56%	194.47Cr
VELOXIS PHARMACEUTICALS A/S	-0.50%	164.41Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-47.93%	162.57Cr

Specialty & Advanced Pharmaceuticals